MediWound Ltd. (NASDAQ:MDWD - Get Free Report) has earned an average recommendation of "Buy" from the five ratings firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $31.80.
MDWD has been the subject of several analyst reports. HC Wainwright set a $31.00 target price on MediWound and gave the stock a "buy" rating in a research report on Thursday, May 22nd. Wall Street Zen raised MediWound to a "sell" rating in a research report on Friday, March 21st. Craig Hallum began coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target on the stock. Alliance Global Partners began coverage on MediWound in a research note on Friday, May 2nd. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Oppenheimer began coverage on MediWound in a report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 target price on the stock.
Check Out Our Latest Stock Report on MDWD
MediWound Stock Performance
Shares of MDWD opened at $19.39 on Friday. The stock has a market capitalization of $209.61 million, a price-to-earnings ratio of -9.28 and a beta of 0.38. MediWound has a 52 week low of $14.14 and a 52 week high of $24.00. The stock has a fifty day moving average of $19.53 and a 200-day moving average of $18.19.
MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. During the same quarter last year, the business earned ($1.05) EPS. As a group, equities analysts forecast that MediWound will post -2.66 EPS for the current year.
Institutional Trading of MediWound
Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its position in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 481 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after acquiring an additional 999 shares during the last quarter. Corebridge Financial Inc. grew its position in shares of MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 665 shares during the period. Nuveen LLC purchased a new stake in shares of MediWound during the 1st quarter worth approximately $168,000. Finally, Deutsche Bank AG raised its holdings in shares of MediWound by 2,255.2% in the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 6,044 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.
About MediWound
(
Get Free ReportMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
